EE9800105A - Dendriitrakke stimuleeriv faktor - Google Patents

Dendriitrakke stimuleeriv faktor

Info

Publication number: EE9800105A
Authority: EE; Estonia
Prior art keywords: stimulating factor; dendritic cell; cell stimulating; dendritic cells; cells
Prior art date: 1995-10-04

Application number

EE9800105A

Other languages

English (en)

Estonian (et)

Inventor

D. Lyman Stewart

R. Mckenna Hilary

H. Lynch David

Brasel Kenneth

Maraskovsky Eugene

Original Assignee

Immunex Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-04

Filing date

1996-10-03

Publication date

1998-10-15

1996-10-03 Application filed by Immunex Corporation filed Critical Immunex Corporation

1998-10-15 Publication of EE9800105A publication Critical patent/EE9800105A/xx

Links

210000004443 dendritic cell Anatomy 0.000 title abstract 4
230000004936 stimulating effect Effects 0.000 title 1
102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 abstract 2
101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
210000000130 stem cell Anatomy 0.000 abstract 1
239000012646 vaccine adjuvant Substances 0.000 abstract 1
229940124931 vaccine adjuvant Drugs 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Hematology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Mycology (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Compositions Of Macromolecular Compounds (AREA)

EE9800105A 1995-10-04 1996-10-03 Dendriitrakke stimuleeriv faktor EE9800105A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53914295A	1995-10-04	1995-10-04
PCT/US1996/015990 WO1997012633A1 (en)	1995-10-04	1996-10-03	Dendritic cell stimulatory factor

Publications (1)

Publication Number	Publication Date
EE9800105A true EE9800105A (et)	1998-10-15

Family

ID=24149974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9800105A EE9800105A (et)	1995-10-04	1996-10-03	Dendriitrakke stimuleeriv faktor

Country Status (23)

Country	Link
EP (1)	EP0871487B1 (cs)
JP (1)	JP3631496B2 (cs)
KR (2)	KR100676792B1 (cs)
CN (1)	CN1172718C (cs)
AT (1)	ATE432085T1 (cs)
AU (1)	AU697539B2 (cs)
BR (1)	BR9610802A (cs)
CA (1)	CA2232865A1 (cs)
CZ (1)	CZ97798A3 (cs)
DE (1)	DE69637942D1 (cs)
EA (1)	EA199800272A1 (cs)
EE (1)	EE9800105A (cs)
ES (1)	ES2323818T3 (cs)
IS (1)	IS4703A (cs)
LV (1)	LV12085B (cs)
NO (1)	NO981374L (cs)
NZ (1)	NZ321039A (cs)
PL (1)	PL187329B1 (cs)
RO (1)	RO120579B1 (cs)
SI (1)	SI9620116A (cs)
SK (1)	SK40898A3 (cs)
TR (1)	TR199800607T1 (cs)
WO (1)	WO1997012633A1 (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US9068164B1 (en) *	1995-02-02	2015-06-30	Tristem Trading (Cyprus) Limited	Method of preparing an undifferentiated cell
KR20000022445A (ko) *	1996-07-10	2000-04-25	크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카	수상돌기 세포의 활성화 방법
AUPO388396A0 (en) *	1996-11-27	1996-12-19	Ludwig Institute For Cancer Research	Cellular adjuvant
AU7835898A (en) *	1997-06-17	1999-01-04	Immunex Corporation	A method of enhancing antigen-specific peripheral immune tolerance
FR2775692B1 (fr) *	1998-03-03	2000-06-16	Roussy Inst Gustave	Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US6849452B1 (en)	1998-03-03	2005-02-01	Institut Gustave Roussy	Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2782524B1 (fr) *	1998-08-21	2002-07-19	Roussy Inst Gustave	Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
DK1733735T3 (en)	1998-05-22	2017-06-19	Ottawa Hospital Res Inst	Methods and products for the induction of mucosal immunity
WO1999062537A1 (en) *	1998-06-04	1999-12-09	The Rockefeller University	Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6291661B1 (en)	1998-07-02	2001-09-18	Immunex Corporation	flt3-L mutants and method of use
US6838086B1 (en)	1998-08-27	2005-01-04	Universitaetsklinikum Freiburg	Composition comprising low molecular weight hyaluronic acid fragments
GB9827604D0 (en) *	1998-12-15	1999-02-10	Lorantis Ltd	Methods of immunosuppression
WO2001009303A2 (en) *	1999-07-30	2001-02-08	Vical Inc.	Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
EP1240343A2 (en) *	1999-11-03	2002-09-18	Powderject Vaccines, Inc.	Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
AU2001239873A1 (en) *	2000-02-24	2001-09-03	The Board Of Trustees Of The Leland Stanford Junior University	Adjuvant treatment by in vivo activation of dendritic cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
EP1276501B9 (en) *	2000-04-25	2007-01-24	Immunex Corporation	Method for treatment of tumors using photodynamic therapy
US20040247563A1 (en) *	2000-11-02	2004-12-09	Lynch David H.	Method of enhancing lymphocyte-mediated immune responses
WO2002040044A2 (en) *	2000-11-17	2002-05-23	Immunex Corporation	Chemoattractant recruitment of dendritic cells for enhancement of immunization
EP2322603B1 (en) *	2001-09-06	2019-10-16	NorthWest Biotherapeutics, Inc.	Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response
KR100490308B1 (ko) *	2002-02-25	2005-05-17	크레아젠 주식회사	면역 치료용 성숙화된 수지상 세포 백신의 제조방법
JP2005528373A (ja) *	2002-03-26	2005-09-22	イミュネックス・コーポレーション	免疫プロトコルにＦｌｔ３リガンドを用いる方法
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) *	2002-11-28	2005-10-19	주식회사 바이넥스	면역 치료용 수지상 세포의 제조방법
KR100614220B1 (ko) *	2004-11-08	2006-08-21	고려대학교 산학협력단	Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
DE102005016234B4 (de) *	2005-04-08	2008-05-15	Tgc Biomics Gmbh	Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen
KR100818215B1 (ko)	2006-10-11	2008-04-01	재단법인서울대학교산학협력재단	Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법
KR101264811B1 (ko)	2011-05-20	2013-05-15	충남대학교산학협력단	마이코박테리움 압세수스의 ＭＡＢ０９８１ｃ 단백질을 이용한 수지상 세포의 성숙방법
CN109563481B (zh) *	2016-07-13	2024-01-05	俄亥俄州创新基金会	用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
CN113544152B (zh)	2018-12-18	2024-10-15	勃林格殷格翰国际加拿大公司	Flt3激动剂抗体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US826250A (en)	1905-12-20	1906-07-17	Albert Huck	Switch for toy railways.
US4714680B1 (en)	1984-02-06	1995-06-27	Univ Johns Hopkins	Human stem cells
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
EP0790307A1 (en)	1986-12-16	1997-08-20	Gist-Brocades B.V.	Molecular cloning and expression of human IL-3
OA09736A (en)	1987-02-18	1993-11-30	Schering Biotech Corp	"Human interleukin-3 and muteins thereof".
EP0391892A4 (en)	1987-10-30	1990-11-28	Immunex Corporation	Nonglycosylated analogs of human colony stimulating factors
US5073627A (en)	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
US5108910A (en)	1989-08-22	1992-04-28	Immunex Corporation	DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
DK0423980T3 (da)	1989-10-16	2000-10-09	Amgen Inc	Stamcellefaktor
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
ATE220715T1 (de)	1991-10-23	2002-08-15	Nexell Therapeutics Inc	Verfahren zur selektiven vermehrung von cd34 positiven zellen
US5554512A (en)	1993-05-24	1996-09-10	Immunex Corporation	Ligands for flt3 receptors
NZ314644A (en)	1993-05-24	2000-11-24	Immunex Corp	Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5405772A (en) *	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells

1996
- 1996-10-03 EA EA199800272A patent/EA199800272A1/ru unknown
- 1996-10-03 DE DE69637942T patent/DE69637942D1/de not_active Expired - Lifetime
- 1996-10-03 KR KR1020047011434A patent/KR100676792B1/ko not_active Expired - Fee Related
- 1996-10-03 NZ NZ321039A patent/NZ321039A/en unknown
- 1996-10-03 AT AT96936216T patent/ATE432085T1/de not_active IP Right Cessation
- 1996-10-03 WO PCT/US1996/015990 patent/WO1997012633A1/en not_active Ceased
- 1996-10-03 AU AU73922/96A patent/AU697539B2/en not_active Ceased
- 1996-10-03 CN CNB96197351XA patent/CN1172718C/zh not_active Expired - Fee Related
- 1996-10-03 EE EE9800105A patent/EE9800105A/xx unknown
- 1996-10-03 RO RO98-00824A patent/RO120579B1/ro unknown
- 1996-10-03 JP JP51449097A patent/JP3631496B2/ja not_active Expired - Fee Related
- 1996-10-03 SI SI9620116A patent/SI9620116A/sl unknown
- 1996-10-03 CA CA002232865A patent/CA2232865A1/en not_active Abandoned
- 1996-10-03 PL PL96325964A patent/PL187329B1/pl not_active IP Right Cessation
- 1996-10-03 KR KR10-1998-0702286A patent/KR100514957B1/ko not_active Expired - Fee Related
- 1996-10-03 TR TR1998/00607T patent/TR199800607T1/xx unknown
- 1996-10-03 BR BR9610802A patent/BR9610802A/pt unknown
- 1996-10-03 CZ CZ98977A patent/CZ97798A3/cs unknown
- 1996-10-03 SK SK408-98A patent/SK40898A3/sk unknown
- 1996-10-03 ES ES96936216T patent/ES2323818T3/es not_active Expired - Lifetime
- 1996-10-03 EP EP96936216A patent/EP0871487B1/en not_active Expired - Lifetime
1998
- 1998-03-26 IS IS4703A patent/IS4703A/is unknown
- 1998-03-26 NO NO981374A patent/NO981374L/no unknown
- 1998-04-02 LV LVP-98-63A patent/LV12085B/en unknown

Also Published As

Publication number	Publication date
EA199800272A1 (ru)	1998-10-29
KR100514957B1 (ko)	2005-11-25
NZ321039A (en)	2001-03-30
LV12085A (lv)	1998-07-20
ATE432085T1 (de)	2009-06-15
SI9620116A (sl)	1999-08-31
KR20040079421A (ko)	2004-09-14
SK40898A3 (en)	1999-04-13
IS4703A (is)	1998-03-26
CN1229359A (zh)	1999-09-22
CN1172718C (zh)	2004-10-27
NO981374D0 (no)	1998-03-26
WO1997012633A1 (en)	1997-04-10
KR100676792B1 (ko)	2007-02-02
AU697539B2 (en)	1998-10-08
CA2232865A1 (en)	1997-04-10
ES2323818T3 (es)	2009-07-24
JP3631496B2 (ja)	2005-03-23
RO120579B1 (ro)	2006-04-28
JPH11513389A (ja)	1999-11-16
EP0871487B1 (en)	2009-05-27
EP0871487A1 (en)	1998-10-21
AU7392296A (en)	1997-04-28
NO981374L (no)	1998-06-03
TR199800607T1 (xx)	1998-06-22
BR9610802A (pt)	1999-07-13
PL325964A1 (en)	1998-08-17
EP0871487A4 (en)	2004-09-01
PL187329B1 (pl)	2004-06-30
CZ97798A3 (cs)	1999-02-17
DE69637942D1 (de)	2009-07-09
LV12085B (en)	1998-09-20
KR19990063818A (ko)	1999-07-26

Publication	Publication Date	Title
NO981374D0 (no)	1998-03-26	Dendrittcellestimulerende faktor
IL114444A0 (en)	1995-11-27	Multi-stage cascade boosting vaccine
NZ333607A (en)	2000-08-25	Method of stimulating the immune system by transfecting dendritic cells
DK0633929T3 (da)	2004-06-28	Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
DE69418856D1 (de)	1999-07-08	Targeting von immunogenen durch lysosomen
EA200200517A1 (ru)	2002-10-31	Клеточная везикула, называемая "экзосома", ее получение и применение для стимуляции иммунного ответа
DK66692D0 (da)	1992-05-21	En mammal cytokin, il-11
IL98957A0 (en)	1992-07-15	Immunotherapy with interleukin-7
NZ322910A (en)	2000-05-26	Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
DE69329344D1 (de)	2000-10-05	Spezifische modulationen des immunsystems
DE69839273D1 (de)	2008-04-30	Krebs immuntherapie mit semi-allogenen zellen
CY1110235T1 (el)	2015-01-14	Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
DK0843731T3 (da)	2008-06-09	Adenovirusvektorer til genterapi
DE50008756D1 (de)	2004-12-30	Peptid aus antigen muc-1 zur auslösung einer immunreaktion gegen tumorzellen
Vischer	1972	Mitogenic factors produced by lymphocyte activation: effect on T-and B-cells
DE60130634D1 (de)	2007-11-08	Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
ATE385809T1 (de)	2008-03-15	Saponin-zusammensetzungen und deren verwendung
Sofra et al.	2009	Antigen‐loaded ER microsomes from APC induce potent immune responses against viral infection
ES2012815A6 (es)	1990-04-16	Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma, y para preparar vacunas que los contienen.
DE69835615D1 (de)	2006-09-28	Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen
Szostak	1997	Rekombinante Bakteriunhuellen als Impfstoffe.
MX9606317A (es)	1998-01-31	Metodos para la activacion de celulas t in vivo por celulas dentriticas impulsadas por antigenos.